ARCHIVES

In Sign-Off Of Two Orphan Drugs, ODAC Leaves Efficacy Interpretation To Docs

This article is from The Cancer Letter archive.

Vol. 24 No. 45 | November 27, 1998

Download PDF Visit The Full Archive

Related Articles

AACR Supports Bypass Budget; Public Consortium Sequences Mouse Genome

May 10, 2002

NCS Heeds Bloch’s Plea, To Consider Establishing Separate PDQ-Like System For General Public Use

December 7, 1984

Zometa Can Reduce Risk Of Skeletal-Related Events

August 26, 2011

Talpin To Join NCI

June 27, 2003

NCI CTEP Approved Trials For the Month of September

September 27, 2013

Amgen Web Site For Patients Goes Dark After Story In The Cancer Letter.

November 16, 2007